Literature DB >> 29214494

Guinea pig complement potently measures vibriocidal activity of human antibodies in response to cholera vaccines.

Kyoung Whun Kim1,2,3, Soyoung Jeong1, Ki Bum Ahn1,4, Jae Seung Yang3, Cheol-Heui Yun2,5, Seung Hyun Han6.   

Abstract

The vibriocidal assay using guinea pig complement is widely used for the evaluation of immune responses to cholera vaccines in human clinical trials. However, it is unclear why guinea pig complement has been used over human complement in the measurement of vibriocidal activity of human sera and there have not been comparison studies for the use of guinea pig complement over those from other species. Therefore, we comparatively investigated the effects of complements derived from human, guinea pig, rabbit, and sheep on vibriocidal activity. Complements from guinea pig, rabbit, and human showed concentration-dependent vibriocidal activity in the presence of quality control serum antibodies. Of these complements, guinea pig complement was the most sensitive and effective over a wide concentration range. When the vibriocidal activity of complements was measured in the absence of serum antibodies, human, sheep, and guinea pig complements showed vibriocidal activity up to 40-fold, 20-fold, and 1-fold dilution, respectively. For human pre- and post-vaccination sera, the most potent vibriocidal activity was observed when guinea pig complement was used. In addition, the highest fold-increases between pre- and post- vaccinated sera were obtained with guinea pig complement. Furthermore, human complement contained a higher amount of V. cholerae- and its lipopolysaccharide-specific antibodies than guinea pig complement. Collectively, these results suggest that guinea pig complements are suitable for vibriocidal assays due to their high sensitivity and effectiveness to human sera.

Entities:  

Keywords:  Vibrio cholerae; cholera vaccine; guinea pig complement; vibriocidal assay

Mesh:

Substances:

Year:  2017        PMID: 29214494     DOI: 10.1007/s12275-017-7478-0

Source DB:  PubMed          Journal:  J Microbiol        ISSN: 1225-8873            Impact factor:   3.422


  27 in total

1.  Sensitive microplate assay for detection of bactericidal antibodies to Vibrio cholerae O139.

Authors:  Stephen R Attridge; Camilla Johansson; Dang D Trach; Firdausi Qadri; Ann-Mari Svennerholm
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

Review 2.  Vibrio cholerae O139 Bengal: odyssey of a fortuitous variant.

Authors:  Thandavarayan Ramamurthy; Shinji Yamasaki; Yoshifumi Takeda; Gopinath Balakrish Nair
Journal:  Microbes Infect       Date:  2003-04       Impact factor: 2.700

3.  A SIMPLIFIED METHOD FOR BACTERICIDAL ASSAY OF NATURAL ANTIBODIES AGAINST GRAM-NEGATIVE BACTERIA.

Authors:  W P WEIDANZ; M LANDY
Journal:  Proc Soc Exp Biol Med       Date:  1963 Aug-Sep

4.  Quantitative studies on the bactericidal actions of serum and complement. II. Some implications for the mechanism of the bactericidal reaction.

Authors:  L H MUSCHEL; H P TREFFERS
Journal:  J Immunol       Date:  1956-01       Impact factor: 5.422

5.  A semi-automated vibriocidal assay for improved measurement of cholera vaccine-induced immune responses.

Authors:  Jae Seung Yang; Hye Jin Kim; Cheol-Heui Yun; Seok-Seong Kang; Jintaek Im; Hak-Sung Kim; Seung Hyun Han
Journal:  J Microbiol Methods       Date:  2007-08-31       Impact factor: 2.363

Review 6.  Oral vaccines against cholera.

Authors:  Sunheang Shin; Sachin N Desai; Binod K Sah; John D Clemens
Journal:  Clin Infect Dis       Date:  2011-04-14       Impact factor: 9.079

7.  Antibiodies of the IgG, IgM, and IgA classes in newborn and adult sera reactive with gram-negative bacteria.

Authors:  I R Cohen; L C Norins
Journal:  J Clin Invest       Date:  1968-05       Impact factor: 14.808

8.  The origin of the Haitian cholera outbreak strain.

Authors:  Chen-Shan Chin; Jon Sorenson; Jason B Harris; William P Robins; Richelle C Charles; Roger R Jean-Charles; James Bullard; Dale R Webster; Andrew Kasarskis; Paul Peluso; Ellen E Paxinos; Yoshiharu Yamaichi; Stephen B Calderwood; John J Mekalanos; Eric E Schadt; Matthew K Waldor
Journal:  N Engl J Med       Date:  2010-12-09       Impact factor: 91.245

9.  Antibodies enhance interaction of Vibrio cholerae with intestinal M-like cells.

Authors:  Luz P Blanco; Victor J Dirita
Journal:  Infect Immun       Date:  2006-09-25       Impact factor: 3.441

10.  Coverage and costs of mass immunization of an oral cholera vaccine in Vietnam.

Authors:  Dinh Thiem Vu; M Moshaddeque Hossain; Dinh Son Nguyen; Thai Hoa Nguyen; Malla R Rao; Gia Canh Do; Abdollah Naficy; Thi Ke Nguyen; Camilo J Acosta; Jacqueline L Deen; John D Clemens; Duc Trach Dang
Journal:  J Health Popul Nutr       Date:  2003-12       Impact factor: 2.000

View more
  2 in total

1.  Immunogenicity and protective efficacy of a live, oral cholera vaccine formulation stored outside-the-cold-chain for 140 days.

Authors:  Tew Hui Xian; Kurunathan Sinniah; Chan Yean Yean; Venkateskumar Krishnamoorthy; Mohd Baidi Bahari; Manickam Ravichandran; Guruswamy Prabhakaran
Journal:  BMC Immunol       Date:  2020-05-25       Impact factor: 3.615

2.  A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation.

Authors:  Stephanie Fischinger; Jonathan K Fallon; Ashlin R Michell; Thomas Broge; Todd J Suscovich; Hendrik Streeck; Galit Alter
Journal:  J Immunol Methods       Date:  2019-07-10       Impact factor: 2.303

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.